Saturday 23 December 2006

A Pill for Incontinence?

Pricie Hanna, VP of John Starr Inc, previewed a study done with Helena
Engqvist Consulting on the likely impact of advances in drugs on the market for hygiene products. The prevalence of incontinence is rising due to population ageing and the increasing prevalence of prostate surgery, obesity and diabetes.

By 2050, 20% of the world’s population will be over 60, including 35% of Europe and 26% of the USA. This slide shows the figures for 2020.
Prevalence of Incontinence in 6 major EU Countries, USA and Canada

Treatments and coping strategies used by US women with incontinence (above and below)

The key pharmaceutical companies developing drugs to treat incontinence include Pfizer, J&J, GlaxoSmithKline, Ely Lilly, Novartis, Yamanouchi and P&G. Several new drugs for over-active bladder were introduced in 2004 and 2005 and many more are in the pipeline. Also in 2005, collaborations between P&G and Novartis, Yamanouchi and GlaxoSmithKline and Takeda and Toray were announced, all targeting faster introductions of both prescription and over the counter products to treat incontinence.

No comments: